Drugmakers look to HDL-raising pills as next big seller

11/30/2005 | Forbes

Large pharmaceutical companies, followed closely by smaller competitors, are racing to get onto the market drugs that raise high-density lipoprotein cholesterol levels. Pfizer is betting the $800 million it invested in developing torcetrapib will lead to $1 billion in sales during its first year on the market, but Merck, Roche Holding, Novartis and Kos Pharmaceuticals are close behind.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ